Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

about

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

Item

http://www.wikidata.org/entity/Q55025652

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@en

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@nl

type

Item

label

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@en

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@nl

prefLabel

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@en

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.

@nl

P1476

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil

@en

P2093

Edgardo Kaplinsky

http://www.w3.org/2001/XMLSchema#string

P2860

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

Use of Inotropic Agents in Treatment of Systolic Heart Failure

The ABCs of managing systolic heart failure: Past, present, and future

Angiotensin-neprilysin inhibition versus enalapril in heart failure

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Long-term survival of cancer patients compared to heart failure and stroke: a systematic review.

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

P304

212518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7573/DIC.212518

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gordon Mallarkey

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29707029

http://www.w3.org/2001/XMLSchema#string

P932

5916097

http://www.w3.org/2001/XMLSchema#string